Clinical Trials Directory

Trials / Unknown

UnknownNCT03185494

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Chinese PLA General Hospital · Academic / Other
Sex
All
Age
5 Years – 70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to chemotherapy.

Detailed description

PRIMARY OBJECTIVES: I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD19/CD22 vector (referred to as tanCART-19/22 cells). II. Determine duration of in vivo survival of tanCART-19/22 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of tanCART-19/22TCR (T-cell receptor) zeta:CD137 and TCR zeta cells over time. SECONDARY OBJECTIVES: I. For patients with detectable disease, measure anti-tumor response due to tanCART-19/22 cell infusions. II. CD137 transgene is measured by the relative engraftment levels of tanCART-19/22 CD137 and TCR zeta cells over time. III. Estimate relative trafficking of tanCART-19/22 cells to tumor in bone marrow and lymph nodes. IV. For patients with stored or accessible tumor cells (such as patients with active chronic lymphocytic leukemia(CLL), acute lymphocytic leukemia (ALL), etc) determine tumor cell killing by tanCART-19/22 cells in vitro. V. Determine if cellular or humoral host immunity develops against the murine anti-CD19/22, and assess correlation with loss of detectable tanCART-19/20 (loss of engraftment). VI. Determine the relative subsets of tanCART-19/22 T cells (Tcm, Tem, and Treg). OUTLINE: Patients are assigned to 1 group according to order of enrollment. Patients receive anti-CD19/22-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells on days 0,1, and 2 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 13 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALanti-CD19/22-CAR vector-transduced T cellsgenetically engineered lymphocyte therapy

Timeline

Start date
2017-08-01
Primary completion
2019-08-01
Completion
2020-08-01
First posted
2017-06-14
Last updated
2019-04-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03185494. Inclusion in this directory is not an endorsement.